Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alpha-lipoic acid combined with high molecular weight sodium hyaluronate is formulated as a preservative-free ophthalmic emulsion primarily used to manage oxidative stress and inflammation on the ocular surface, particularly in patients with dry eye disease. Alpha-lipoic acid acts as an antioxidant that can reduce oxidative damage and inflammation, while high molecular weight sodium hyaluronate provides lubrication, hydration, anti-inflammatory effects, and supports tissue repair. The combination shows synergistic benefits improving quality of life scores and markers of oxidative stress and inflammation in dry eye disease patients. This formulation leverages alpha-lipoic acid’s antioxidant properties alongside the viscoelastic and anti-inflammatory actions of high molecular weight sodium hyaluronate to enhance ocular surface health[1][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-lipoic acid + high molecular weight sodium hyaluronate.